ArticleScientific reports2025
Royal jelly ameliorates behavioral deficit and hippocampal damage induced by inhalation exposure to xylene.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well established that inhalation exposure to xylene causes significant learning impairments and neurobehavioral toxicity by altering lipid environments in nerve membranes and affecting neurotransmitter levels. Royal jelly (RJ) has been shown to exhibit potent antioxidant properties that can protect the hippocampus from oxidative damage. The present research was designed to investigate the neuroprotective potential of RJ in mitigating hippocampal injury induced by short-term and long-term xylene inhalation exposure. In this experiment, 48 male Wistar rats were randomly assigned to short-term and long-term groups, each consisting of control, RJ, xylene, and xylene + RJ treatments. Rats were exposed to xylene via inhalation for 6 h daily at a concentration of 500 ppm, while RJ was administered orally at a dose of 200 mg/kg. After 8 weeks, spatial memory and anxiety level were evaluated. Apoptosis and cell necrosis in the hippocampus were identified using the TUNEL method and hematoxylin-eosin staining. Additionally, oxidative stress biomarkers and the expression of apoptosis-related genes in hippocampal tissue were investigated. The results revealed that xylene exposure caused a significant impairment in spatial working memory performance, as reflected by reductions in arm entries and alternation percentage, along with a significant suppression of antioxidant enzyme activities (CAT, TAC, SOD, and GPx) compared to the control group. Additionally, xylene exposure significantly heightened anxiety-like behaviors, elevated MDA levels, increased the number of TUNEL-positive apoptotic cells in the hippocampus, and upregulated the expression of apoptotic markers including caspase-3, Bax, and p53 genes, alongside promoting necrotic cell death. Co-treatment with RJ significantly improved behavioral alterations, enhanced antioxidant activity, and decreased hippocampal apoptosis/necrosis. In conclusion, RJ mitigates xylene-induced neurotoxicity via antioxidant and anti-apoptotic pathways, suggesting therapeutic potential against xylene-related cognitive and neuronal damage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.